New Standard in metastatic colorectal Carcinoma: Anti-angiogenesis follows Anti-angiogenesis

被引：0
作者：
Arnold, Dirk
机构：
来源：
AKTUELLE UROLOGIE | 2013年 / 44卷 / 03期
关键词：
PHASE-3; TRIAL; CANCER; BEVACIZUMAB; VEGF; FLUOROURACIL; OXALIPLATIN; COMBINATION; GROWTH; CHEMOTHERAPY; LEUCOVORIN;
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A2 / A6
页数：5
相关论文
共 19 条
[1]  
Allegra C, 2012, ASCO 2012
[2]  
Arnold D, 2012, ASCO 2012
[3]   Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy [J].
Bagri, Anil ;
Berry, Leanne ;
Gunter, Bert ;
Singh, Mallika ;
Kasman, Ian ;
Damico, Lisa A. ;
Hong Xiang ;
Schmidt, Maike ;
Fuh, Germaine ;
Hollister, Beth ;
Rosen, Oliver ;
Plowman, Greg D. .
CLINICAL CANCER RESEARCH, 2010, 16 (15) :3887-3900
[4]   Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial [J].
Bennouna, Jaafar ;
Sastre, Javier ;
Arnold, Dirk ;
Osterlund, Pia ;
Greil, Richard ;
Van Cutsem, Eric ;
von Moos, Roger ;
Maria Vieitez, Jose ;
Bouche, Olivier ;
Borg, Christophe ;
Steffens, Claus-Christoph ;
Alonso-Orduna, Vicente ;
Schlichting, Christoph ;
Reyes-Rivera, Irmarie ;
Bendahmane, Belguendouz ;
Andre, Thierry ;
Kubicka, Stefan .
LANCET ONCOLOGY, 2013, 14 (01) :29-37
[5]   The biology of VEGF and its receptors [J].
Ferrara, N ;
Gerber, HP ;
LeCouter, J .
NATURE MEDICINE, 2003, 9 (06) :669-676
[6]  
Folkman J, 2005, CANC PRINCIPLES PRAC, V2
[7]   Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200 [J].
Giantonio, Bruce J. ;
Catalano, Paul J. ;
Meropol, Neal J. ;
O'Dwyer, Peter J. ;
Mitchell, Edith P. ;
Alberts, Steven R. ;
Schwartz, Michael A. ;
Benson, Al B., III .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) :1539-1544
[8]   Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial [J].
Grothey, Axel ;
Van Cutsem, Eric ;
Sobrero, Alberto ;
Siena, Salvatore ;
Falcone, Alfredo ;
Ychou, Marc ;
Humblet, Yves ;
Bouche, Olivier ;
Mineur, Laurent ;
Barone, Carlo ;
Adenis, Antoine ;
Tabernero, Josep ;
Yoshino, Takayuki ;
Lenz, Heinz-Josef ;
Goldberg, Richard M. ;
Sargent, Daniel J. ;
Cihon, Frank ;
Cupit, Lisa ;
Wagner, Andrea ;
Laurent, Dirk .
LANCET, 2013, 381 (9863) :303-312
[9]   Noncardiac Vascular Toxicities of Vascular Endothelial Growth Factor Inhibitors in Advanced Cancer: A Review [J].
Keefe, Dorothy ;
Bowen, Joanne ;
Gibson, Rachel ;
Tan, Thean ;
Okera, Meena ;
Stringer, Andrea .
ONCOLOGIST, 2011, 16 (04) :432-444
[10]   Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity [J].
Klement, G ;
Baruchel, S ;
Rak, J ;
Man, S ;
Clark, K ;
Hicklin, DJ ;
Bohlen, P ;
Kerbel, RS .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (08) :R15-R24
12